Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 20.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 17.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 12.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ults may differ materially from these estimates. Item 5.02 Departure of Directors or Certain Officers; Election of Di |
| 27.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
| 10.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointme |
Stammdaten
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Editas Medicine, Inc. |
|---|---|
| Ticker | EDIT |
| CIK | 0001650664 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 299,0 Mio. USD |
| Beta | 2,04 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 40,520,000 | -160,060,000 | -1.80 | 186,534,000 | 27,288,000 |
| 2025-09-30 | 10-Q | 7,543,000 | -25,117,000 | -0.28 | 201,751,000 | 13,453,000 |
| 2025-06-30 | 10-Q | 3,578,000 | -53,235,000 | -0.63 | 210,581,000 | 19,189,000 |
| 2025-03-31 | 10-Q | 4,658,000 | -76,088,000 | -0.92 | 263,652,000 | 62,420,000 |
| 2024-12-31 | 10-K | 32,314,000 | -237,093,000 | -2.88 | 341,589,000 | 134,274,000 |
| 2024-09-30 | 10-Q | 61,000 | -62,141,000 | -0.75 | 327,567,000 | 175,634,000 |
| 2024-06-30 | 10-Q | 513,000 | -67,607,000 | -0.82 | 384,801,000 | 232,009,000 |
| 2024-03-31 | 10-Q | 1,135,000 | -61,950,000 | -0.76 | 440,347,000 | 294,400,000 |
| 2023-12-31 | 10-K | 78,123,000 | -153,219,000 | -2.02 | 499,153,000 | 349,097,000 |
| 2023-09-30 | 10-Q | 5,336,000 | -45,019,000 | -0.55 | 504,650,000 | 360,462,000 |
| 2023-06-30 | 10-Q | 2,887,000 | -40,290,000 | -0.56 | 541,953,000 | 399,917,000 |
| 2023-03-31 | 10-Q | 9,851,000 | -49,036,000 | -0.71 | 464,105,000 | 317,473,000 |
| 2022-12-31 | 10-K | 19,712,000 | -220,432,000 | -3.21 | 514,321,000 | 360,680,000 |
| 2022-09-30 | 10-Q | 42,000 | -55,726,000 | -0.81 | 531,029,000 | 414,745,000 |
| 2022-06-30 | 10-Q | 6,362,000 | -53,453,000 | -0.78 | 580,833,000 | 465,414,000 |
| 2022-03-31 | 10-Q | 6,771,000 | -50,515,000 | -0.74 | 623,108,000 | 512,760,000 |
| 2021-12-31 | 10-K | 25,544,000 | -192,502,000 | -2.85 | 677,483,000 | 553,642,000 |
| 2021-09-30 | 10-Q | 6,197,000 | -39,082,000 | -0.57 | 717,019,000 | 586,794,000 |
| 2021-06-30 | 10-Q | 379,000 | -55,256,000 | -0.81 | 755,880,000 | 613,361,000 |
| 2021-03-31 | 10-Q | 6,499,000 | -56,728,000 | -0.86 | 780,294,000 | 637,996,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-03 | Burkly Linda | Officer, EVP, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -749 | 2.02 | -1,512.68 | -24,0% | |
| 2026-03-03 | O'Neill Gilmore Neil | Director, Officer, CEO | Open Market Sale | -5,394 | 2.02 | -10,894.26 | -172,9% | |
| 2026-03-03 | Parison Amy | Officer, SVP, Chief Financial Officer | Open Market Sale | -474 | 2.02 | -957.48 | -15,2% | |
| 2025-12-03 | Burkly Linda | Officer, EVP, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -713 | 2.15 | -1,535.16 | -24,4% | |
| 2025-12-03 | O'Neill Gilmore Neil | Director, Officer, CEO | Open Market Sale | -5,603 | 2.15 | -12,063.82 | -191,4% | |
| 2025-12-03 | Parison Amy | Officer, SVP, Chief Financial Officer | Open Market Sale | -461 | 2.15 | -992.58 | -15,7% | |
| 2025-09-03 | Parison Amy | Officer, SVP, Chief Financial Officer | Open Market Sale | -458 | 2.60 | -1,189.01 | -18,9% | |
| 2025-09-03 | O'Neill Gilmore Neil | Director, Officer, CEO | Open Market Sale | -5,592 | 2.60 | -14,517.39 | -230,4% | |
| 2025-09-03 | Burkly Linda | Officer, EVP, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -710 | 2.60 | -1,843.23 | -29,2% | |
| 2025-08-07 | Parison Amy | Officer, SVP, Chief Financial Officer | Open Market Sale | -679 | 2.58 | -1,751.82 | -27,8% | |
| 2025-07-31 | Burkly Linda | Officer, EVP, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5,121 | 2.49 | -12,756.92 | -202,4% | |
| 2025-06-03 | O'Neill Gilmore Neil | Director, Officer, CEO | Open Market Sale | -15,192 | 1.72 | -26,195.57 | -415,7% | |
| 2025-06-03 | Parison Amy | Officer, SVP, Chief Financial Officer | Open Market Sale | -446 | 1.72 | -768.90 | -12,2% | |
| 2025-06-03 | Burkly Linda | Officer, EVP, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -726 | 1.72 | -1,251.84 | -19,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.